Literature DB >> 17549824

Evolving issues in male hypogonadism: evaluation, management, and related comorbidities.

Martin M Miner1, Richard Sadovsky.   

Abstract

Hypogonadism in men has a complex and varied pathogenesis. In addition to multiple established causes of the disease, low testosterone levels are associated with various comorbidities, including metabolic syndrome and type 2 diabetes. Symptoms associated with hypogonadism include reduced sex drive, fatigue, and mood disturbances, but accurate diagnosis requires biochemical testing. Total testosterone is considered the appropriate testosterone measurement in most situations in primary care, although free testosterone is a more accurate marker and is indicated in some situations. Testosterone replacement therapy is a valid treatment option for men with testosterone deficiency accompanied by symptoms of hypogonadism. The goals of therapy are to restore physiologic testosterone levels and alleviate symptoms. A potential association of testosterone replacement therapy with prostate cancer is the biggest safety concern, so patient monitoring should include regular digital rectal examination and prostate-specific antigen tests.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17549824     DOI: 10.3949/ccjm.74.suppl_3.s38

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  9 in total

1.  [38 year-old patient with suspected congenital hormonal dysfunction].

Authors:  T Bergmann; E G Hahn; P Lohse; I A Harsch
Journal:  Internist (Berl)       Date:  2010-10       Impact factor: 0.743

2.  Functional, metabolic, and morphologic characteristics of a novel rat model of type 2 diabetes-associated erectile dysfunction.

Authors:  Maarten Albersen; Guiting Lin; Thomas M Fandel; Haiyang Zhang; Xuefeng Qiu; Ching-Shwun Lin; Tom F Lue
Journal:  Urology       Date:  2011-05-31       Impact factor: 2.649

Review 3.  A practical guide to male hypogonadism in the primary care setting.

Authors:  P Dandona; M T Rosenberg
Journal:  Int J Clin Pract       Date:  2010-05       Impact factor: 2.503

4.  Pharmacokinetics and drying time of testosterone 2% gel in men with hypogonadism: a multicenter, open-label, single-arm trial.

Authors:  A Morgentaler; J McGettigan; Q Xiang; T M Danoff; E M Gould
Journal:  Int J Impot Res       Date:  2014-07-24       Impact factor: 2.896

5.  Effective testosterone suppression for prostate cancer: is there a best castration therapy?

Authors:  Leonard G Gomella
Journal:  Rev Urol       Date:  2009

6.  Identifying nutritional, functional, and quality of life correlates with male hypogonadism in advanced cancer patients.

Authors:  Domenico Fuoco; Jonathan di Tomasso; Caroline Boulos; Robert D Kilgour; Jose A Morais; Manuel Borod; Antonio Vigano
Journal:  Ecancermedicalscience       Date:  2015-08-04

7.  Hormonal modulation in aging patients with erectile dysfunction and metabolic syndrome.

Authors:  Inês Campos Costa; Hugo Nogueira Carvalho; Luís Pacheco-Figueiredo; Inês Tomada; Nuno Tomada
Journal:  Int J Endocrinol       Date:  2013-12-28       Impact factor: 3.257

8.  Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors.

Authors:  P M Willemse; J Burggraaf; N A T Hamdy; N I Weijl; C Y Vossen; L van Wulften; A Q M J van Steijn-van Tol; F R Rosendaal; S Osanto
Journal:  Br J Cancer       Date:  2013-05-09       Impact factor: 7.640

Review 9.  Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer-time for a rethink?

Authors:  Sonja Cabarkapa; Marlon Perera; Ken Sikaris; Jonathan S O'Brien; Damien M Bolton; Nathan Lawrentschuk
Journal:  Prostate Int       Date:  2017-06-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.